Diabetic animals, four weeks after the onset of hyperglycemia, treated with HMGB1 inhibitor GLC for four weeks, demonstrated an alleviation of neuroinflammation with decreased expressions of NLRP3, TLR4, and HMGB1 when compared to the diabetic animals with no treatment, as shown by Western blot analysis, which is concomitant with decreased pain behavior in GLC treated diabetic animals as compared to diabetic animals with no treatment (Figure 2a–c). This evidence concerns the gene HMGB1 and Hyperglycemia.